Search filters

List of works by Lawrence A Leiter

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

scientific article published in 2022

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

scientific article published in The Lancet

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.

scientific article

Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

scientific article published on 13 February 2018

Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents -Post-hoc Analyses from DECLARE-TIMI 58

scientific article published on 26 August 2020

Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial

scientific article published on 23 February 2020

Correctly understanding the diabetes data in FOURIER

scientific article published on 04 July 2019

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

scientific article published on 06 March 2020

Declare-Timi 58: Participants' Baseline Characteristics

scientific article published on 11 January 2018

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

scientific article published in June 2017

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study

scientific article published on 16 December 2019

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials

scientific article published on 02 July 2018

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial

scientific article published on 14 September 2017

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.

scientific article published on 11 August 2017

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment

scientific article published on 27 April 2017

Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

scientific article published on 08 April 2019

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials

scientific article published on 26 November 2019

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

scientific article

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults

scientific article published on 10 March 2017

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide

scientific article

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

scientific article published on 28 November 2018

Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II

scientific article

Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study

scientific article

Residual cardiovascular risk among people with diabetes

scientific article published on 01 April 2019

Safety of dapagliflozin in a broad population of patients with type 2 diabetes - analyses from the DECLARE - TIMI 58 study

scientific article published on 02 April 2020

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

scientific article published on 12 June 2018

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

scientific article published on 27 November 2017

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

scientific article published on 16 November 2020

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

scientific article published on 16 November 2020

The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy

scientific article

The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy

article

The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy

scientific article published on May 2012

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension

scientific article published on 29 March 2013

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension

scientific article

The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension

scientific article published on May 2015

The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

scientific article published on 28 March 2019

The cost-effectiveness of dapagliflozin in treating high risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial

scientific article published on 28 December 2020

The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of LEADER and SUSTAIN 6 trials

scientific article published on 06 May 2020

The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double-blind, randomized, controlled, acute feeding, equivalence trial

scientific article published on 25 June 2018

Paulina is supported by:

About Paulina

Help